A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2017
At a glance
- Drugs IMO 2125 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Idera Pharmaceuticals
- 25 Sep 2017 Planned number of patients changed from 40 to 75.
- 12 May 2017 Status changed from not yet recruiting to recruiting.
- 11 Apr 2017 According to an Idera Pharmaceuticals media release, patient enrollment has been activated in this trial and the first patient is expected to enroll early this quarter.